Avanos Medical, Inc.(AVNS)Earnings, Financials & Key Ratios

AVNS•NYSE

$24.70

$1.15B mkt cap·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryRespiratory and sleep therapy devices

AboutAvanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Show more

Revenue$701M+1.9%
EBITDA-$33M-138.1%
Net Income-$68M+82.7%
EPS (Diluted)-1.46+82.9%
Gross Margin49.77%-10.2%
EBITDA Margin-4.65%-137.4%
Operating Margin-8.78%-251.1%
Net Margin-9.68%+83.0%
ROE-8.45%+77.7%
ROIC-5.41%-302.7%
Debt/Equity0.17-19.2%
Interest Coverage-15.55+51.5%

Technical→

AVNS Key Insights

Avanos Medical, Inc. (AVNS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Trading near 52-week high
✓Trading at only 1.5x book value

✗Weaknesses

✗Profits declining 20.1% over 5 years

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AVNS Price & Volume

Avanos Medical, Inc. (AVNS) stock price & volume — 10-year historical chart

Loading chart...

AVNS Growth Metrics

Avanos Medical, Inc. (AVNS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-7.77%

5 Years-0.38%

3 Years0.83%

TTM3.87%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM81.96%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM648.36%

Return on Capital

10 Years1.1%

5 Years1.92%

3 Years0.34%

Last Year-6.5%

AVNS Recent Earnings

Avanos Medical, Inc. (AVNS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 5, 2026

EPS

$0.22

Est $0.16

+37.5%

Revenue

$182M

Est $170M

+7.2%

Q1 2026

Feb 24, 2026

EPS

$0.29

Est $0.24

+20.8%

Revenue

$181M

Est $175M

+3.5%

Q4 2025

Nov 5, 2025

EPS

$0.22

Est $0.12

+83.3%

Revenue

$178M

Est $165M

+8.1%

Q3 2025

Aug 5, 2025

EPS

$0.17

Est $0.18

-5.6%

Revenue

$175M

Est $168M

+4.5%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.22vs $0.16+37.5%	$182Mvs $170M+7.2%
Q1 2026	Feb 24, 2026	$0.29vs $0.24+20.8%	$181Mvs $175M+3.5%
Q4 2025	Nov 5, 2025	$0.22vs $0.12+83.3%	$178Mvs $165M+8.1%
Q3 2025	Aug 5, 2025	$0.17vs $0.18-5.6%	$175Mvs $168M+4.5%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
MMSIMerit Medical Systems, Inc.Direct Competitor	3.61B	60.44	28.38	11.66%	9.03%	8.95%	5.98%	0.57
NVCRNovoCure LimitedDirect Competitor	1.81B	15.88	-13.02	8.28%	-25.66%	-50.82%		0.85
ITGRInteger Holdings CorporationDirect Competitor	2.95B	85.85	29.71	7.57%	7.67%	8.23%	3.56%	0.80
ATRCAtriCure, Inc.Direct Competitor	1.49B	29.44	-122.67	14.88%	-2.14%	-2.43%	3.24%	0.18
NTRANatera, Inc.Direct Competitor	28.44B	206.77	-135.14	56.75%	-14.61%	-24.69%	0.24%	0.16
HOLXHologic, Inc.Product Competitor	16.97B	76.01	30.53	1.74%	13.18%	10.37%	5.42%	0.52
ICUIICU Medical, Inc.Product Competitor	2.89B	117.01	3900.33	-6.33%	-0.32%	-0.35%	3.18%	0.60
ANGOAngioDynamics, Inc.Product Competitor	455.65M	10.96	-13.20	-3.76%	-9.02%	-15.71%

Compare AVNS vs Peers

Avanos Medical, Inc. (AVNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MMSI

Most directly comparable listed peer for AVNS.

Scale Benchmark

vs SYK

Larger-name benchmark to compare AVNS against a more recognizable public peer.

Peer Set

Compare Top 5

vs MMSI, NVCR, ITGR, ATRC

AVNS Income Statement

Avanos Medical, Inc. (AVNS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	611.6M	652.3M	697.6M	714.8M	744.6M	684.1M	673.3M	687.8M	701.2M	715.9M
Revenue Growth %	8.02%	6.65%	6.94%	2.47%	4.17%	-8.13%	-1.58%	2.15%	1.95%	3.87%
Cost of Goods Sold	274.7M	261.4M	295.4M	324.2M	364.7M	289.9M	293.6M	306.5M	352.2M	362.5M
COGS % of Revenue	44.91%	40.07%	42.35%	45.36%	48.98%	42.38%	43.61%	44.56%	50.23%	-
Gross Profit	336.9M▲ 0%	390.9M▲ 16.0%	402.2M▲ 2.9%	390.6M▼ 2.9%	379.9M▼ 2.7%	394.2M▲ 3.8%	379.7M▼ 3.7%	381.3M▲ 0.4%	349M▼ 8.5%	353.4M▲ 0%
Gross Margin %	55.08%	59.93%	57.65%	54.64%	51.02%	57.62%	56.39%	55.44%	49.77%	49.36%
Gross Profit Growth %	13.36%	16.03%	2.89%	-2.88%	-2.74%	3.76%	-3.68%	0.42%	-8.47%	-
Operating Expenses	352.9M	356M	407.6M	319.7M	293.1M	352.3M	314.7M	341.3M	410.6M	333.3M
OpEx % of Revenue	57.7%	54.58%	58.43%	44.73%	39.36%	51.5%	46.74%	49.62%	58.56%	-
Selling, General & Admin	314.7M	314.2M	369.9M	284.8M	260.8M	323.1M	287.5M	315.1M	218.3M	218.9M
SG&A % of Revenue	51.46%	48.17%	53.02%	39.84%	35.03%	47.23%	42.7%	45.81%	31.13%	-
Research & Development	38.2M	41.8M	37.7M	34.9M	32.3M	30.6M	27.2M	26.2M	23.1M	22.9M
R&D % of Revenue	6.25%	6.41%	5.4%	4.88%	4.34%	4.47%	4.04%	3.81%	3.29%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	169.2M	1000K
Operating Income	-16M▲ 0%	34.9M▲ 318.1%	-5.4M▼ 115.5%	70.9M▲ 1413.0%	86.8M▲ 22.4%	41.9M▼ 51.7%	65M▲ 55.1%	40M▼ 38.5%	-61.6M▼ 254.0%	-60M▲ 0%
Operating Margin %	-2.62%	5.35%	-0.77%	9.92%	11.66%	6.12%	9.65%	5.82%	-8.78%	-8.38%
Operating Income Growth %	76.95%	318.13%	-115.47%	1412.96%	22.43%	-51.73%	55.13%	-38.46%	-254%	-
EBITDA	24M	68.4M	31.5M	113.8M	125.1M	83M	108.5M	85.5M	-32.6M	-20.5M
EBITDA Margin %	3.92%	10.49%	4.52%	15.92%	16.8%	12.13%	16.11%	12.43%	-4.65%	-2.86%
EBITDA Growth %	184.51%	185%	-53.95%	261.27%	9.93%	-33.65%	30.72%	-21.2%	-138.13%	-121.29%
D&A (Non-Cash Add-back)	40M	33.5M	36.9M	42.9M	38.3M	41.1M	43.5M	45.5M	29M	39.5M
EBIT	-40.6M	3.5M	-49M	-44.9M	10.6M	36.7M	7.1M	-391.1M	-62.2M	-70.2M
Net Interest Income	-29.1M	-18.6M	-8.3M	-14.4M	-3.1M	-8.8M	-12.1M	-7.1M	-800K	-4M
Interest Income	2.5M	7.8M	6.7M	1.2M	200K	1.2M	2.9M	5.1M	3.2M	1.9M
Interest Expense	31.6M	26.4M	15M	15.6M	3.3M	10M	15M	12.2M	4M	4.2M
Other Income/Expense	-56.2M	-53M	-58.6M	-131.4M	-79.5M	-15.2M	-72.9M	-443.3M	-4.6M	-8.3M
Pretax Income	-72.2M▲ 0%	-18.1M▲ 74.9%	-64M▼ 253.6%	-60.5M▲ 5.5%	7.3M▲ 112.1%	26.7M▲ 265.8%	-7.9M▼ 129.6%	-403.3M▼ 5005.1%	-66.2M▲ 83.6%	-68.3M▲ 0%
Pretax Margin %	-11.81%	-2.77%	-9.17%	-8.46%	0.98%	3.9%	-1.17%	-58.64%	-9.44%	-9.54%
Income Tax	-40.1M	-9.6M	-18.1M	-33.3M	1M	5.2M	2M	-17M	1.7M	-3.9M
Effective Tax Rate %	55.54%	53.04%	28.28%	55.04%	13.7%	19.48%	-25.32%	4.22%	-2.57%	5.71%
Net Income	79.3M▲ 0%	57.5M▼ 27.5%	-45.9M▼ 179.8%	-27.2M▲ 40.7%	6.3M▲ 123.2%	50.5M▲ 701.6%	-61.8M▼ 222.4%	-392.1M▼ 534.5%	-67.9M▲ 82.7%	-69.4M▲ 0%
Net Margin %	12.97%	8.82%	-6.58%	-3.81%	0.85%	7.38%	-9.18%	-57.01%	-9.68%	-9.69%
Net Income Growth %	99.25%	-27.49%	-179.83%	40.74%	123.16%	701.59%	-222.38%	-534.47%	82.68%	81.96%
Net Income (Continuing)	-32.1M	-8.5M	-45.9M	-27.2M	6.3M	21.5M	-9.9M	-386.3M	-67.9M	-69.4M
Discontinued Operations	111.4M	66M	0	0	0	29M	-51.9M	-5.8M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	1.69▲ 0%	1.22▼ 27.8%	-0.96▼ 178.7%	-0.57▲ 40.6%	0.13▲ 122.8%	1.07▲ 723.1%	-1.33▼ 224.3%	-8.53▼ 541.4%	-1.46▲ 82.9%	-▲ 0%
EPS Growth %	98.82%	-27.81%	-178.69%	40.63%	122.81%	723.08%	-224.3%	-541.35%	82.88%	648.36%
EPS (Basic)	1.69	1.22	-0.96	-0.57	0.13	1.08	-1.33	-8.53	-1.46	-
Diluted Shares Outstanding	46.8M	47.2M	47.6M	47.8M	48.6M	47.3M	46.6M	46M	46.4M	0
Basic Shares Outstanding	46.52M	47.2M	47.6M	47.8M	48.1M	46.9M	46.6M	46M	46.4M	0
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

AVNS Balance Sheet

Avanos Medical, Inc. (AVNS) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	1.16B	713.6M	538.5M	467.2M	427.6M	624.1M	487M	393.4M	355.4M	325M
Cash & Short-Term Investments	219.7M	384.5M	205.3M	111.5M	118.5M	127.7M	87.7M	107.7M	89.8M	65.6M
Cash Only	219.7M	384.5M	205.3M	111.5M	118.5M	127.7M	87.7M	107.7M	89.8M	65.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	203M	150.5M	163.8M	167.9M	131.2M	167.9M	142.8M	132.8M	103.8M	103M
Days Sales Outstanding	121.15	84.21	85.7	85.74	64.31	89.58	77.41	70.47	54.03	54.59
Inventory	91.1M	121.4M	145.9M	168.9M	159.3M	132.3M	163.2M	138.8M	148M	141.3M
Days Inventory Outstanding	121.05	169.51	180.28	190.16	159.43	166.57	202.89	165.29	153.38	146.65
Other Current Assets	632.5M	57.2M	0	0	0	196.2M	93.3M	14.1M	13.8M	15.1M
Total Non-Current Assets	1.04B	1.12B	1.26B	1.21B	1.18B	1.16B	1.21B	760.8M	718.3M	725.1M
Property, Plant & Equipment	109.9M	154.1M	248.5M	223.6M	206.7M	146.1M	144M	144.8M	141M	150.5M
Fixed Asset Turnover	5.57x	4.23x	2.81x	3.20x	3.60x	4.68x	4.68x	4.75x	4.97x	4.92x
Goodwill	764.7M	783.6M	800.9M	802.5M	801.6M	760.3M	796.1M	455.6M	394.9M	394M
Intangible Assets	148.9M	168.2M	184.3M	157.7M	141.2M	234.2M	239.5M	112.3M	117.8M	114.7M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	4.1M	7.6M	11.3M	11.8M	16.5M	17.6M	19.3M	23.2M	31.5M	144.7M
Total Assets	2.2B▲ 0%	1.83B▼ 16.5%	1.8B▼ 1.8%	1.67B▼ 7.0%	1.6B▼ 4.1%	1.79B▲ 11.4%	1.69B▼ 5.3%	1.15B▼ 31.8%	1.07B▼ 7.0%	1.05B▲ 0%
Asset Turnover	0.28x	0.36x	0.39x	0.43x	0.46x	0.38x	0.40x	0.60x	0.65x	0.68x
Asset Growth %	5.99%	-16.51%	-1.84%	-7.05%	-4.14%	11.43%	-5.29%	-31.8%	-6.97%	-85.04%
Total Current Liabilities	389.8M	264.3M	212.5M	166.3M	139.2M	191M	234.6M	165.9M	165.2M	131.2M
Accounts Payable	171.2M	169.9M	83M	67.6M	56.4M	67.9M	56.3M	54.3M	55.5M	52.3M
Days Payables Outstanding	227.48	237.24	102.56	76.11	56.45	85.49	69.99	64.66	57.52	53.06
Short-Term Debt	39.8M	0	0	0	0	6.2M	8.6M	9.4M	10.2M	21.3M
Deferred Revenue (Current)	144.9M	0	0	0	0	0	0	0	0	0
Other Current Liabilities	134.3M	0	0	0	0	7.1M	108.7M	73.3M	0	109.9M
Current Ratio	2.98x	2.70x	2.53x	2.81x	3.07x	3.27x	2.08x	2.37x	2.15x	2.15x
Quick Ratio	2.74x	2.24x	1.85x	1.79x	1.93x	2.57x	1.38x	1.53x	1.26x	1.26x
Cash Conversion Cycle	14.72	16.49	163.42	199.78	167.3	170.67	210.31	171.1	149.89	148.18
Total Non-Current Liabilities	590.7M	271.9M	321.9M	250M	193.8M	304.7M	221.5M	159.8M	130.3M	136.8M
Long-Term Debt	541.1M	247.7M	248.1M	180M	130M	226.3M	159.4M	125.3M	90.3M	117.1M
Capital Lease Obligations	0	0	62.6M	53.3M	42.8M	32.5M	28.3M	24.6M	20.4M	63.6M
Deferred Tax Liabilities	17.8M	4.4M	0	5.7M	11.9M	25.4M	23.8M	5.5M	6.1M	18M
Other Non-Current Liabilities	31.8M	19.8M	11.2M	11M	9.1M	20.5M	10M	4.4M	13.5M	58.9M
Total Liabilities	980.5M	536.2M	534.4M	416.3M	333M	495.7M	456.1M	325.7M	295.5M	268M
Total Debt	580.9M	247.7M	325.4M	248.8M	187.5M	277M	209.1M	170.2M	129.1M	138.4M
Net Debt	361.2M	-136.8M	120.1M	137.3M	69M	149.3M	121.4M	62.5M	39.3M	72.8M
Debt / Equity	0.48x	0.19x	0.26x	0.20x	0.15x	0.21x	0.17x	0.21x	0.17x	0.17x
Debt / EBITDA	24.20x	3.62x	10.33x	2.19x	1.50x	3.34x	1.93x	1.99x	-	-6.75x
Net Debt / EBITDA	15.05x	-2.00x	3.81x	1.21x	0.55x	1.80x	1.12x	0.73x	-	-3.55x
Interest Coverage	-1.28x	0.13x	-3.27x	-2.88x	3.21x	3.67x	0.47x	-32.06x	-15.55x	-16.71x
Total Equity	1.22B▲ 0%	1.3B▲ 6.7%	1.27B▼ 2.5%	1.26B▼ 0.7%	1.27B▲ 1.1%	1.29B▲ 1.6%	1.24B▼ 4.3%	828.5M▼ 33.0%	778.2M▼ 6.1%	782.1M▲ 0%
Equity Growth %	10.24%	6.73%	-2.47%	-0.69%	1.12%	1.62%	-4.25%	-32.99%	-6.07%	-86.1%
Book Value per Share	25.97	27.48	26.58	26.29	26.14	27.30	26.53	18.01	16.77	16.77
Total Shareholders' Equity	1.22B	1.3B	1.27B	1.26B	1.27B	1.29B	1.24B	828.5M	778.2M	782.1M
Common Stock	500K	500K	500K	500K	500K	500K	500K	500K	500K	500K
Retained Earnings	-299.9M	-242.4M	-288.3M	-315.5M	-303.6M	-253.1M	-314.9M	-707M	-779.9M	-774.8M
Treasury Stock	-4.4M	-5.3M	-8.9M	-9.8M	-21.3M	-66.8M	-85.9M	-99M	-102.3M	0
Accumulated OCI	-31.3M	-33.7M	-32M	-28.1M	-33.8M	-35.8M	-27M	-44.6M	-32M	-36M
Minority Interest	0	0	0	0	0	0	0	0	0	0

AVNS Cash Flow Statement

Avanos Medical, Inc. (AVNS) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	144.2M	-145.6M	-74.5M	-2.5M	87.3M	90.9M	32.4M	100.7M	74.7M	74.7M
Operating CF Margin %	23.58%	-22.32%	-10.68%	-0.35%	11.72%	13.29%	4.81%	14.64%	10.65%	-
Operating CF Growth %	-23.62%	-200.97%	48.83%	96.64%	3592%	4.12%	-64.36%	210.8%	-25.82%	-313.83%
Net Income	79.3M	57.5M	-45.9M	-27.2M	5.2M	50.5M	-61.8M	-392.1M	-72.9M	-69.4M
Depreciation & Amortization	59.5M	33.5M	36.9M	42.9M	38.3M	47.7M	46.1M	45.5M	38.9M	39.5M
Stock-Based Compensation	12.6M	10.5M	10.5M	12.1M	13.2M	15.9M	15.8M	13.8M	0	7.6M
Deferred Taxes	-6.2M	3.7M	-6.5M	25.9M	-3.4M	0	0	0	0	0
Other Non-Cash Items	3.3M	-107.4M	-9.9M	11.6M	8M	1.1M	50.3M	398.5M	98.9M	58.9M
Working Capital Changes	-4.3M	-143.4M	-59.6M	-67.8M	26M	-24.3M	-18M	35M	9.8M	5.1M
Change in Receivables	-15.3M	67.4M	-800K	45.8M	-10.8M	-24.7M	39M	-6.6M	30.9M	5.8M
Change in Inventory	-16.8M	-34.5M	-21.3M	-21.8M	17.2M	-30.9M	4.7M	39M	200K	-1M
Change in Payables	18.8M	-64M	-83.6M	-18.9M	-11.9M	35.4M	-14.4M	-900K	600K	7M
Cash from Investing	-43.1M	639.5M	-108.1M	-24.2M	-21M	-135.4M	21.6M	-27.5M	-60.6M	-59.2M
Capital Expenditures	-43.2M	-49.1M	-50.6M	-20.2M	-21M	-19.3M	-17.8M	-17.8M	-31.6M	-29.2M
CapEx % of Revenue	7.06%	7.53%	7.25%	2.83%	2.82%	2.82%	2.64%	2.59%	4.51%	-
Acquisitions	100K	688.6M	-57.5M	-4M	0	-116.1M	39.4M	-9.7M	-28M	-1.9M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	100K	754.3M	0	0	0	0	0	0	-1M	-28.1M
Cash from Financing	2.2M	-324.4M	1.5M	-70M	-55.3M	56.7M	-94.2M	-49.1M	-37M	-11.1M
Debt Issued (Net)	0	-339M	-200K	-69.8M	-50M	103.4M	-64.7M	-33.6M	-34.4M	-7.1M
Equity Issued (Net)	-2.5M	-900K	-3.6M	-900K	-11.5M	-45.5M	-19.1M	-12.8M	-2.6M	-800K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-2.5M	-900K	-3.6M	-900K	-11.5M	-45.5M	-19.1M	-12.8M	-3.3M	-2.4M
Other Financing	4.7M	15.5M	5.3M	700K	6.2M	-1.2M	-10.4M	-2.7M	0	-3.2M
Net Change in Cash	106M▲ 0%	164.8M▲ 55.5%	-179.2M▼ 208.7%	-93.8M▲ 47.7%	7M▲ 107.5%	9.2M▲ 31.4%	-40M▼ 534.8%	20M▲ 150.0%	-17.9M▼ 189.5%	-31.4M▲ 0%
Free Cash Flow	101M▲ 0%	-194.7M▼ 292.8%	-125.1M▲ 35.7%	-22.7M▲ 81.9%	66.3M▲ 392.1%	71.6M▲ 8.0%	14.6M▼ 79.6%	82.9M▲ 467.8%	43.1M▼ 48.0%	7.5M▲ 0%
FCF Margin %	16.51%	-29.85%	-17.93%	-3.18%	8.9%	10.47%	2.17%	12.05%	6.15%	1.05%
FCF Growth %	-36.76%	-292.77%	35.75%	81.85%	392.07%	7.99%	-79.61%	467.81%	-48.01%	-93.42%
FCF per Share	2.16	-4.13	-2.63	-0.47	1.36	1.51	0.31	1.80	0.93	0.93
FCF Conversion (FCF/Net Income)	1.82x	-2.53x	1.62x	0.09x	13.86x	1.80x	-0.52x	-0.26x	-1.10x	-0.11x
Interest Paid	28.7M	20.6M	16.7M	0	0	0	14.7M	11.5M	6.5M	0
Taxes Paid	21.4M	96.6M	8.4M	0	0	0	23.6M	3.3M	14.1M	0

AVNS Key Ratios

Avanos Medical, Inc. (AVNS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	6.84%	4.58%	-3.58%	-2.16%	0.5%	3.94%	-4.89%	-37.98%	-8.45%	-8.91%
Return on Invested Capital (ROIC)	-0.76%	1.91%	-0.32%	3.83%	4.76%	2.26%	3.48%	2.67%	-5.41%	-5.41%
Gross Margin	55.08%	59.93%	57.65%	54.64%	51.02%	57.62%	56.39%	55.44%	49.77%	49.36%
Net Margin	12.97%	8.82%	-6.58%	-3.81%	0.85%	7.38%	-9.18%	-57.01%	-9.68%	-9.69%
Debt / Equity	0.48x	0.19x	0.26x	0.20x	0.15x	0.21x	0.17x	0.21x	0.17x	0.17x
Interest Coverage	-1.28x	0.13x	-3.27x	-2.88x	3.21x	3.67x	0.47x	-32.06x	-15.55x	-16.71x
FCF Conversion	1.82x	-2.53x	1.62x	0.09x	13.86x	1.80x	-0.52x	-0.26x	-1.10x	-0.11x
Revenue Growth	8.02%	6.65%	6.94%	2.47%	4.17%	-8.13%	-1.58%	2.15%	1.95%	3.87%

AVNS SEC Filings & Documents

Avanos Medical, Inc. (AVNS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Apr 14, 2026·SEC

Material company update

Mar 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 21, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 5, 2025·SEC

AVNS Frequently Asked Questions

Avanos Medical, Inc. (AVNS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Avanos Medical, Inc. (AVNS) reported $715.9M in revenue for fiscal year 2025. This represents a 57% decrease from $1.68B in 2012.

Avanos Medical, Inc. (AVNS) grew revenue by 1.9% over the past year. Growth has been modest.

Avanos Medical, Inc. (AVNS) reported a net loss of $69.4M for fiscal year 2025.

Dividend & Returns

Avanos Medical, Inc. (AVNS) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.

Avanos Medical, Inc. (AVNS) generated $7.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More AVNS

Avanos Medical, Inc. (AVNS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Avanos Medical, Inc.(AVNS)Earnings, Financials & Key Ratios

AVNS Key Insights

✓Strengths

✗Weaknesses

AVNS Price & Volume

AVNS Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

AVNS Recent Earnings

AVNS Peer Comparison

Compare AVNS vs Peers

vs MMSI

vs SYK

Compare Top 5

AVNS Income Statement

AVNS Balance Sheet

AVNS Cash Flow Statement

AVNS Key Ratios

AVNS SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

AVNS Frequently Asked Questions

Explore More AVNS

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation